menu
    • menu
    [{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for adamantan-1-amine hydrochloride

    Menu

    adamantan-1-amine hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Strides Pharma Science

    India
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Strides Receives USFDA Approval for Amantadine Hydrochloride Softgel Capsules

    Details : USFDA approved generic version of Amantadine Hydrochloride, a NMDA inhibitor, which is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.

    Product Name : Symmetrel-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    February 21, 2022

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Zydus Lifesciences

    India arrow
    DCAT Week
    Not Confirmed

    Zydus Lifesciences

    India arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zydus Receives USFDA Approval for Amantadine Extended-Release Capsules

    Details : Amantadine Hydrochloride, a NMDA inhibitor, which is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.

    Product Name : Gocovri-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 03, 2024

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Upsher-Smith Laboratories

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Upsher-Smith Laboratories

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Bora Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

    Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.

    Product Name : Amantadine HCl-Generic

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    April 01, 2024

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Bora Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Upsher-Smith Laboratories

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Upsher-Smith Laboratories

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Bora Pharmaceuticals

    Deal Size : $210.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

    Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.

    Product Name : Amantadine HCl-Generic

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 18, 2024

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Bora Pharmaceuticals

    Deal Size : $210.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Supernus Pharmaceuticals

    Deal Size : $450.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    Details : Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiv...

    Product Name : Gocovri

    Product Type : Small molecule

    Upfront Cash : $450.0 million

    November 24, 2021

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Supernus Pharmaceuticals

    Deal Size : $450.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Supernus Pharmaceuticals

    Deal Size : $450.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

    Details : The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s...

    Product Name : Gocovri

    Product Type : Small molecule

    Upfront Cash : $450.0 million

    October 11, 2021

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Supernus Pharmaceuticals

    Deal Size : $450.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    New Data Analysis Supports GOCOVRI for Motor Complications for People With PD

    Details : At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).

    Product Name : Gocovri

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 10, 2021

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Adamas Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Adamas Publishes New Data Analyses Demonstrating GOCOVRI Treatment More Than Doubled ON Time Without Dyskinesi...

    Details : Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia.

    Product Name : Gocovri

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 29, 2021

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Osmotica Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Osmotica Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Adamas Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Adamas Completes Acquisition of OSMOLEX ER®

    Details : Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopamin...

    Product Name : Osmolex ER

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 05, 2021

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Adamas Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Osmotica Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Osmotica Pharmaceuticals

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Adamas Pharmaceuticals

    Deal Size : $7.5 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas

    Details : Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.

    Product Name : Osmolex ER

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 02, 2020

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Adamas Pharmaceuticals

    Deal Size : $7.5 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth